Compare FSP & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSP | IPHA |
|---|---|---|
| Founded | 1981 | 1999 |
| Country | United States | France |
| Employees | 28 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 165.3M |
| IPO Year | 2001 | 2014 |
| Metric | FSP | IPHA |
|---|---|---|
| Price | $0.34 | $1.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | ★ 887.2K | 37.5K |
| Earning Date | 04-28-2026 | 03-26-2026 |
| Dividend Yield | ★ 6.34% | N/A |
| EPS Growth | ★ 15.69 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $107,162,000.00 | N/A |
| Revenue This Year | $17.91 | $180.36 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.32 | $1.18 |
| 52 Week High | $1.70 | $2.71 |
| Indicator | FSP | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 41.18 | 33.84 |
| Support Level | $0.32 | $1.67 |
| Resistance Level | $0.41 | $1.83 |
| Average True Range (ATR) | 0.02 | 0.10 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 30.70 | 11.85 |
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.